All In Biotech

Drug Trial Radar · NCT07410117

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants With Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,120

Planned (sponsor's estimate)

Start

Mar 9, 2026

Primary completion

Jan 23, 2030

Study completion May 6, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

  • Cancer-Associated Thrombosis (CAT)

Interventions

  • REGN7508Drug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related deathTime frame: Through 6 months
  2. Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleedingTime frame: Through 6 months

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • Bioresearch Partner- Hialeah Hospital

    Hialeah, Florida · Recruiting

  • Helios Clinical Research

    North Miami Beach, Florida · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • El Paso Medical Research Institute (Medresearch Inc)

    El Paso, Texas · Withdrawn

  • American Hospital Tbilisi

    Tbilisi, Georgia · Recruiting

  • Israel Georgia Medical Research Clinic Helsicore

    Tbilisi, Georgia · Recruiting

  • Llc Todua Clinic

    Tbilisi, Georgia · Recruiting

  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

    Tbilisi, Georgia · Recruiting

  • Institute of Clinical Oncology

    Tbilisi, Georgia · Recruiting

  • JSC Evex Hospitals - Caraps Medline

    Tbilisi, Georgia · Recruiting

  • LTD Cancer Research Centre

    Tbilisi, Georgia · Recruiting

  • Caucasus Medical Centre

    Tbilisi, Georgia · Recruiting

  • LTD High Technology Hospital Medcenter

    Batumi, Adjara, Georgia · Recruiting

  • Krystyna Kiel Oncology Center

    Kutaisi, Imereti, Georgia · Recruiting

  • Niigata University Medical & Dental Hospital

    Niigata, Japan · Recruiting

  • Ehime University Hospital

    Tōon, Ehime, Japan · Recruiting

  • Gunma Prefectural Cancer Center

    Ōta, Gunma, Japan · Recruiting

  • Hyogo Cancer Center

    Akashi, Hyōgo, Japan · Recruiting

  • Kagawa University Hospital

    Kita-gun, Kagawa-ken, Japan · Recruiting

  • Tokai University Hospital

    Isehara-Shi, Kanagawa, Japan · Recruiting

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, Japan · Recruiting

  • Tohoku University Hospital

    Sendai, Miyagi, Japan · Recruiting

  • National Hospital Organization Osaka National Hospital (ONH)

    Chuo, Osaka, Japan · Recruiting

  • Saitama Cancer Center

    Ina-machi, Saitama, Japan · Recruiting

  • National Cancer Center Hospital - Tsukiji Campus

    Chuo Ku, Tokyo, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku, Tokyo, Japan · Recruiting

  • Yamaguchi University Hospital

    Ube, Yamaguchi, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.